BioAge Labs, Inc. (BIOA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The reporting period covers the three and nine months ended September 30, 2025. The Company's lead product candidate, BGE-102 (an NLRP3 inhibitor for obesity and cardiovascular risk factors), entered Phase 1 clinical trials in August 2025. The Company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $2,054 | $0 | $5,917 | $0 |
| Total Operating Expenses | $25,194 | $24,750 | $70,274 | $52,832 |
| Net Loss | $(20,171) | $(23,407) | $(54,662) | $(49,980) |
| Net Loss Per Share (Basic/Diluted) | $(0.56) | $(6.70) | $(1.52) | $(21.76) |
| Cash, Cash Equivalents & Marketable Securities | $295,878 | $354,349 | $295,878 | $334,474 |
| Term Loan Principal Outstanding | $3,500 | $8,000 | $3,500 | $8,000 |
Note: Cash and marketable securities as of Sept 30, 2025, totaled $295.9 million ($215.6M cash + $70.2M current marketable securities + $10.1M long-term marketable securities).
Material Changes vs. Prior Period
- Revenue Recognition: The Company recognized $2.1 million in collaboration revenue for Q3 2025 (and $5.9 million for the nine months) derived from a new agreement with Novartis Pharma AG. No collaboration revenue was recognized in the comparable 2024 periods.
- Operating Expenses: Total operating expenses increased by 33% year-over-year for the nine-month period ($70.3M vs. $52.8M). This was driven by a 24% increase in R&D expenses and a 60% increase in G&A expenses.
- R&D Shift: R&D costs for the former lead candidate, azelaprag, decreased significantly ($17.5M reduction for 9M 2025) following the termination of its development in January 2025. This was offset by increased spending on the BGE-102 program ($9.5M increase) and new APJ agonist programs ($15.0M increase).
- Other Income: Net other income increased significantly due to higher interest income on cash balances ($10.3M for 9M 2025 vs. $5.5M for 9M 2024) and reduced interest expense due to principal payments on the Term Loan.
Guidance, Outlook, and Risks
- Clinical Outlook: The Company expects initial Phase 1 Single Ascending Dose (SAD) data for BGE-102 by year-end 2025 and complete Phase 1 results by mid-2026. A proof-of-concept trial is planned following Phase 1 completion, with top-line data anticipated in the second half of 2026.
- Liquidity: Management estimates that existing cash, cash equivalents, and marketable securities ($295.9 million) are sufficient to fund operations and capital expenses through 2029.
- Capital Markets: In October 2025, the Company filed a shelf registration statement (Form S-3) permitting the offering of up to $250.0 million in securities. A concurrent Sales Agreement with Leerink Partners LLC allows for the sale of up to $75.0 million of common stock.
- Risks: Key risks include the uncertainty of clinical trial outcomes for BGE-102, the potential for adverse safety signals (as seen with the terminated azelaprag program), reliance on third-party manufacturers (including in China and India), and ongoing securities litigation filed in January 2025 regarding the IPO.
Investor Verification Checklist
- Cash Runway: Verify the $295.9 million cash balance and the 2029 liquidity projection against current burn rates.
- Novartis Agreement: Review the terms of the Novartis collaboration, specifically the $20.0 million upfront/research funding and the $530.0 million potential milestone structure.
- BGE-102 Timeline: Monitor the anticipated year-end 2025 release of Phase 1 SAD data for safety and pharmacokinetic readouts.
- Legal Proceedings: Track the status of the securities class action lawsuit filed on January 7, 2025, alleging violations related to the IPO.
- Debt Obligations: Confirm the repayment schedule for the remaining $3.5 million Term Loan principal, which matures on April 1, 2026.